Zai Lab (ZLAB) Projected to Post Quarterly Earnings on Thursday

Zai Lab (NASDAQ:ZLAB) is projected to issue its quarterly earnings data before the market opens on Thursday, February 27th. Analysts expect the company to announce earnings of ($0.65) per share and revenue of $110.15 million for the quarter. Parties interested in registering for the company’s conference call can do so using this link.

Zai Lab Stock Down 2.5 %

Shares of NASDAQ:ZLAB opened at $32.95 on Tuesday. Zai Lab has a 12-month low of $13.48 and a 12-month high of $36.60. The stock has a market cap of $3.61 billion, a PE ratio of -11.90 and a beta of 1.02. The business has a 50 day moving average of $27.03 and a 200-day moving average of $25.44.

Analyst Ratings Changes

Separately, Cantor Fitzgerald raised Zai Lab to a “strong-buy” rating in a report on Wednesday, February 5th.

Insider Buying and Selling

In other Zai Lab news, insider Rafael Amado sold 7,583 shares of the firm’s stock in a transaction that occurred on Tuesday, December 31st. The shares were sold at an average price of $26.28, for a total value of $199,281.24. Following the sale, the insider now owns 33,834 shares in the company, valued at $889,157.52. This trade represents a 18.31 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. 13.88% of the stock is currently owned by company insiders.

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis.